Facteurs prédictifs de la toxicité hépatique de la radio-embolisation par microsphères marquées à l'Yttrium-90 dans les hépatocarcinomes

Giudice, A.; Bernard, Claire; Detry, Olivier; Delwaide, Jean; Lamproye, Anne; Honoré, Pierre; Hustinx, Roland; Jadoul, Alexandre

doi:10.1016/j.mednuc.2021.12.002

Article (Scientific journals)

Facteurs prédictifs de la toxicité hépatique de la radio-embolisation par microsphères marquées à l'Yttrium-90 dans les hépatocarcinomes

Giudice, A.; Bernard, Claire; Detry, Olivier et al.

2022 • In Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique, 46 (1), p. 1 - 9

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/329613

DOI
10.1016/j.mednuc.2021.12.002

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

1-s2.0-S0928125821002436-main.pdf

Author postprint (403.6 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Hepatocarcinoma; Microspheres; Radioembolization; Therapy; Yttrium 90; Biophysics; Radiological and Ultrasound Technology; Radiology, Nuclear Medicine and Imaging

Abstract :

[en] Introduction: The toxicity associated with hepatic radioembolization (RE) by microspheres labeled with Yttrium 90 (90Y) has a very variable incidence between studies and depends on a multitude of parameters. The objective of this study is to assess the various predictive factors of this toxicity, inherent of the patient or the type of procedure. Patients and methods: Single-center retrospective study including 85 patients with hepatocarcinoma treated by hepatic RE. The medico-technical and clinical-biological parameters were studied over a defined time interval and the toxicity of the latter graded according to the Common Terminology Criteria for Adverse Events. Dosimetry was carried out on the basis of the 90Y PET/CT using the “Simplicit90Y” software and the statistical analysis using the “SAS” software. Results: Post-RE hepatotoxicity observed in 77.7% of our population with maximum grade 3 toxicity in 10.6% of cases. The presence post-RE of hyperbilirubinemia and ascites were detected in 32.1% (only grade 1-2) and 27.1% (4.7% grade 3) of patients, respectively. The pre-therapeutic presence of cirrhosis and/or hyperbilirubin are predictive of post-RE toxicity. Other biological elements studied are less relevant in practice. Radioembolization-induced liver disease (REILD) was observed in 15.3% of cases, mainly of moderate form (13.0%). No impact of the dosimetric approach was observed. Conclusion: A personalized dosimetric approach does not generate additional side effects, while maximizing the tumor dose and therefore the therapeutic effect. The presence of cirrhosis and hyperbilirubinemia pre-RE seem to be the two predominant in the appearance of REILD.

Disciplines :

Radiology, nuclear medicine & imaging

Author, co-author :

Giudice, A.; Service de médecine nucléaire et imagerie oncologique, centre hospitalier universitaire à Liège, Liège, Belgium

Bernard, Claire ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de médecine nucléaire et imagerie onco

Detry, Olivier ; Centre Hospitalier Universitaire de Liège - CHU > > Service de chirurgie abdo, sénologique, endocrine et de transplantation

Delwaide, Jean ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive

Lamproye, Anne ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive

Honoré, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > > Service de chirurgie abdo, sénologique, endocrine et de transplantation

Hustinx, Roland ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de médecine nucléaire et imagerie onco

Jadoul, Alexandre ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de médecine nucléaire et imagerie onco

Language :

French

Title :

Facteurs prédictifs de la toxicité hépatique de la radio-embolisation par microsphères marquées à l'Yttrium-90 dans les hépatocarcinomes

Publication date :

February 2022

Journal title :

Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique

ISSN :

0928-1258

eISSN :

1878-6820

Publisher :

Elsevier Masson s.r.l.

Volume :

Issue :

Pages :

1 - 9

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://api.elsevier.com/content/article/PII:S0928125821002436?httpAccept=text/xml

Available on ORBi :

since 21 March 2025

Statistics

Number of views

48 (1 by ULiège)

Number of downloads

34 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Schubiger, P.A., Beer, H.F., Geiger, L., Rösler, H., Zimmermann, A., Triller, J., 90Y-resin particles – animal experiments on pigs with regard to the introduction of superselective embolization therapy. Int J Rad Appl Instrum B 18 (1991), 305–311.
Andrews, J.C., Walker, S.C., Ackermann, R.J., Cotton, L.A., Ensminger, W.D., Shapiro, B., Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 35 (1994), 1637–1644 [PMID: 7931662].
Sangro, B., Iñarrairaegui, M., Bilbao, J.I., Radioembolization for hepatocellular carcinoma. J Hepatol 56 (2012), 464–473.
Giammarile, F., Bodei, L., Chiesa, C., Flux, G., Forrer, F., Kraeber-Bodere, F., et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging 38 (2011), 1393–1406.
Spreafico, C., Maccauro, M., Mazzaferro, V., Chiesa, C., The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE). Eur J Nucl Med Mol Imaging 41 (2014), 634–638.
Radosa, C.G., Radosa, J.C., Grosche-Schlee, S., Zöphel, K., Plodeck, V., Kühn, J.P., et al. Holmium-166 radioembolization in hepatocellular carcinoma: feasibility and safety of a new treatment option in clinical practice. Cardiovasc Intervent Radiol 42 (2019), 405–412.
Prince, J.F., van den Bosch, M.A.A.J., Nijsen, J.F.W., Smits, M.L.J., van den Hoven, A.F., Nikolakopoulos, S., et al. Efficacy of radioembolization with 166Ho-microspheres in salvage patients with liver metastases: a phase 2 study. J Nucl Med 59 (2018), 582–588.
Dezso, K., Bugyik, E., Papp, V., László, V., Döme, B., Tóvári, J., Development of arterial blood supply in experimental liver metastases. Am J Pathol 175 (2009), 835–843.
Yang, B., Liang, J., Qu, Z., Yang, F., Liao, Z., Gou, H., Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: a systematic review. PLoS One, 15, 2020, e0227475.
Braat, M.N., van Erpecum, K.J., Zonnenberg, B.A., van den Bosch, M.A., Lam, M.G., Radioembolization-induced liver disease: a systematic review. Eur J Gastroenterol Hepatol 29 (2017), 144–152.
Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017, US Department of Health and Human Services [https://www.eortc.be/services/doc/ctc/ctcae_4.03_2010-06-14_quickreference_5x7.pdf].
Peterson, J.L., Vallow, L.A., Johnson, D.W., Heckman, M.G., Diehl, N.N., Smith, A.A., et al. Complications after 90Y microsphere radioembolization for unresectable hepatic tumors: an evaluation of 112 patients. Brachytherapy 12 (2013), 573–579.
Sangro, B., Gil-Alzugaray, B., Rodriguez, J., Sola, I., Martinez-Cuesta, A., Viudez, A., et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 112 (2008), 1538–1546.
Giammarile, F., Bodei, L., Chiesa, C., Flux, G., Forrer, F., Kraeber-Bodere, F., et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging 38 (2011), 1393–1406.
Garin, E., Tselikas, L., Guiu, B., Chalaye, J., Edeline, J., de Baere, T., et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 6 (2021), 17–29.
Levillain, H., Bagni, O., Deroose, C.M., Dieudonné, A., Gnesin, S., Grosser, O.S., et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging 48 (2021), 1570–1584.
Ho, S., Lau, W.Y., Leung, T.W., Chan, M., Johnson, P.J., Li, A.K., Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 24 (1997), 293–298.
Fernandez-Ros, N., Iñarrairaegui, M., Paramo, J.A., Berasain, C., Avila, M.A., Chopitea, A., et al. Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation. Liver Int 35 (2015), 1590–1596.
Strigari, L., Sciuto, R., Rea, S., Carpanese, L., Pizzi, G., Soriani, A., et al. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med 51 (2010), 1377–1385 [Epub 2010 Aug 18. PMID: 20720056].
Rühl, R., Seidensticker, M., Peters, N., Mohnike, K., Bornschein, J., Schütte, K., et al. Hepatocellular carcinoma and liver cirrhosis: assessment of the liver function after Yttrium-90 radioembolization with resin microspheres or after CT-guided high-dose-rate brachytherapy. Dig Dis 27 (2009), 189–199.
Golfieri, R., Bilbao, J.I., Carpanese, L., Cianni, R., Gasparini, D., Ezziddin, S., et al. European Network on Radioembolization with Yttrium-90 Microspheres (ENRY) study collaborators. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. J Hepatol 59 (2013), 753–761.
Hilgard, P., Hamami, M., Fouly, A.E., Scherag, A., Müller, S., Ertle, J., et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 52 (2010), 1741–1749.
Gil-Alzugaray, B., Chopitea, A., Iñarrairaegui, M., Bilbao, J.I., Rodriguez-Fraile, M., Rodriguez, J., et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 57 (2013), 1078–1087.
Walrand, S., Hesse, M., Jamar, F., Lhommel, R., A hepatic dose-toxicity model opening the way toward individualized radioembolization planning. J Nucl Med 55 (2014), 1317–1322.
Lam, M.G., Louie, J.D., Iagaru, A.H., Goris, M.L., Sze, D.Y., Safety of repeated yttrium-90 radioembolization. Cardiovasc Intervent Radiol 36 (2013), 1320–1328.
Seidensticker, R., Seidensticker, M., Damm, R., Mohnike, K., Schütte, K., Malfertheiner, P., et al. Hepatic toxicity after radioembolization of the liver using (90)Y-microspheres: sequential lobar versus whole liver approach. Cardiovasc Intervent Radiol 35 (2012), 1109–1118.
Salem, R., Lewandowski, R.J., Mulcahy, M.F., Riaz, A., Ryu, R.K., Ibrahim, S., et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138 (2010), 52–64.
Sangro, B., Carpanese, L., Cianni, R., Golfieri, R., Gasparini, D., Ezziddin, S., et al. European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY). Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 54 (2011), 868–878.
Goin, J.E., Salem, R., Carr, B.I., Dancey, J.E., Soulen, M.C., Geschwind, J.F., et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 16 (2005), 205–213.
Garin, E., Rolland, Y., Pracht, M., Le Sourd, S., Laffont, S., Mesbah, H., et al. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with 90 Y-loaded glass microsphere radioembolization. Liver Int 37 (2017), 101–110.
Nalesnik, M.A., Federle, M., Buck, D., Fontes, P., Carr, B.I., Hepatobiliary effects of 90yttrium microsphere therapy for unresectable hepatocellular carcinoma. Hum Pathol 40 (2009), 125–134.
Bester, L., Feitelson, S., Milner, B., Chua, T.C., Morris, D.L., Impact of prior hepatectomy on the safety and efficacy of radioembolization with yttrium-90 microspheres for patients with unresectable liver tumors. Am J Clin Oncol 37 (2014), 454–460.
Garin, E., Rolland, Y., Laffont, S., Edeline, J., Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres. Eur J Nucl Med Mol Imaging 43 (2016), 559–575.
Chan, K.T., Alessio, A.M., Johnson, G.E., Vaidya, S., Kwan, S.W., Monsky, W., et al. Prospective trial using internal pair-production positron emission tomography to establish the Yttrium-90 radioembolization dose required for response of hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 101 (2018), 358–365.
Hermann, A.-L., Dieudonné, A., Maxime, R., Manuel, P., Helena, C., Gilles, C., et al. Role of 99mTc-macroaggregated albumin SPECT/CT-based dosimetry in predicting survival and tumor response of patients with locally advanced and inoperable hepatocellular carcinoma (HCC) treated by selective intra-arterial radiation therapy (SIRT) with yttrium-90 resin microspheres, a cohort from SARAH study. J Hepatol, 68, 2018, S13.
Chan, K.T., Alessio, A.M., Johnson, G.E., Vaidya, S., Kwan, S.W., Monsky, W., et al. Prospective trial using internal pair-production positron emission tomography to establish the Yttrium-90 radioembolization dose required for response of hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 101 (2018), 358–365.
Jadoul, A., Bernard, C., Lovinfosse, P., Gérard, L., Lilet, H., Cornet, O., et al. Comparative dosimetry between 99mTc-MAA SPECT/CT and 90Y PET/CT in primary and metastatic liver tumors. Eur J Nucl Med Mol Imaging 47 (2020), 828–837.
Van, B.J., Dewaraja, Y.K., Sangogo, M.L., Mikell, J.K., Y-90 SIRT: evaluation of TCP variation across dosimetric models. EJNMMI Phys, 8, 2021, 45.